Optimi Health announces the opening of Canada's largest GMP-grade psilocybin cultivation operating, including a 10,000 square foot production facility.
Articles
Incannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M
Incannex Healthcare announces a "shareholder loyalty option" to raise A$23.6 million (US$16.5 million). For every two shares purchased, investors will receive a "piggyback option".
TRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II PSILOCYBIN-ASSISTED THERAPY CLINICAL TRIAL
Tryp Therapeutics announces initial patient enrollment in its Phase II clinical trial of a psilocybin-based compound (TRP-8802) for Binge Eating Disorder.
Is The Psychedelic Drug Industry Entering A New Phase?
Several major new deals in the psychedelics industry already in 2022 suggest that the industry could be moving on to its next phase of evolution.
Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies
Field Trip announces its corporate decision to separate Field Trip Health and Field Trip Discovery into separate companies.
Is Minera Alamos Revolutionizing Gold Mining For The 21st Century?
Minera Alamos' "new" model for successful gold mining in the 21st century has a very retro flair to it.
Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets
Private psychedelics company, Terran Biosciences announces a drug development partnership with Sanofi S.A. for the development and commercialization of two late-stage CNS drugs.
Psychedelic Drug Patenting: Still Only Scratching The Surface
Dozens of psychedelic drugs to research. Several "generations" of R&D ahead. To say that we're early in the game with psychedelic drug research is an understatement.
TRYP THERAPEUTICS INC. Announces Amendment to Terms of Private Placement and Closing of $3,000,000 Second Tranche
Tryp Therapeutics closes the second tranche of its recently announced private placement for gross proceeds of CAD$3 million. Units are priced at CAD$0.15.
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
The "Shark Tank" star predicts three of the biggest psychedelic companies will merge into a mega corporation, but our resident Psychedelic Investor wonders: Should they?
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
Cybin announces a new clinical partner as it prepares for its Phase 1/2a clinical trial for CYB003.
Revitalist Reports Fourteen Months of Consecutive Monthly Visit Growth and a 466% Increase Year over Year for March 2022
Revitalist Lifestyle and Wellness announces 14th consecutive month of revenues growth and projects further growth across its network of 9 clinics.
Looking For The Perfect Inflation Hedge? Try This Company
Inflation is rapidly eroding our purchasing power and consuming our wealth. Here is a powerful antidote for investors.
Looking For The Perfect Inflation Hedge? Try This Company
Inflation is rapidly eroding our purchasing power and consuming our wealth. Here is a powerful antidote for investors.
Veterans Push to Persuade Lawmakers to Legalize Therapeutic Use of Psychedelics
New studies have indicated psilocybin could be useful in the treatment of everything from major depression to alcoholism.